STANDARD BIOTOOLS INC. - 10-Q Filing

Standard BioTools Inc. reports Q3 2026 financial results including restructuring charges and updates on SomaScan business segment.

SEC EDGAR ·

Tickers: $LAB

Read the full article at SEC EDGAR

More Regulatory news